Funding Opportunity RFA-DA-20-020 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to solicit research applications for technologies with commercialization potential that aim to improve the utilization of wastewater testing for dynamic monitoring of illicit drugs

Funding Opportunity RFA-DA-20-021 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to solicit research applications for technologies with commercialization potential that aim to improve the utilization of wastewater testing for dynamic monitoring of illicit drugs

Funding Opportunity PAR-19-281 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications that propose the complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://www.niaid.nih.gov/research/role).

Funding Opportunity PAR-19-282 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying SUD, including fundamental brain function relevant to substance use. This FOA is particularly designed to support exploratory/developmental projects requiring budgets that would exceed that allowed for the R21 mechanism (Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional)

Notice NOT-MH-19-029 from the NIH Guide for Grants and Contracts

Notice NOT-HD-19-011 from the NIH Guide for Grants and Contracts

Notice NOT-DA-19-036 from the NIH Guide for Grants and Contracts

Notice NOT-NS-19-060 from the NIH Guide for Grants and Contracts

Notice NOT-EB-19-012 from the NIH Guide for Grants and Contracts

Notice NOT-AG-19-024 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-285 from the NIH Guide for Grants and Contracts. The overall goal of the Fogarty International Center (FIC) HIV Research Training Program is to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research on the evolving HIV epidemic in their countries. This FOA encourages collaborative applications from U.S. and LMIC institutions to support training to achieve technical, administration and financial management expertise required for one of the six research infrastructure functions considered critical to a successful high quality research environment: Research administration and management; Research integrity oversight; Ethical review of research for the protection of human subjects; Laboratory animal welfare oversight Health sciences library and information services; and Information and communications technology systems (ICT) for research Research infrastructure training programs will maximize previous investments and further strengthen the LMIC institution's research capabilities, and provide more accessible research infrastructure training opportunities to others in their own country and in other LMICs.

Funding Opportunity PAR-19-283 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications for research training programs to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research relevant to the evolving HIV epidemic in their country.

Funding Opportunity PAR-19-284 from the NIH Guide for Grants and Contracts. The overall goal of the Fogarty International Center (FIC) HIV Research Training Program is to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research related to the evolving HIV epidemic in their country.

Funding Opportunity PAR-19-279 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for research projects designed to solve specific problems and paradoxes in multiple myeloma (MM) and disparities research identified by the National Cancer Institute (NCI) as the NCIs Multiple Myeloma Disparities Provocative Questions (MMD PQs). These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in multiple myeloma research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of multiple myeloma and disparities research that are deemed important but have not received sufficient attention. The FOA includes 6 Multiple Myeloma PQs that represent diverse fields relevant to multiple myeloma disparities research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific MMD PQ selected from the list. Projects proposed to address specific MMD PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

Funding Opportunity PAR-19-280 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for research projects designed to solve specific problems and paradoxes in multiple myeloma (MM) and disparities research identified as the National Cancer Institute's (NCI) Multiple Myeloma Disparities Provocative Questions (MMD PQs). These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in multiple myeloma research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of multiple myeloma and disparities research that are deemed important but have not received sufficient attention.

Funding Opportunity RFA-NS-19-019 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement (U54) applications from multidisciplinary groups of investigators to accelerate the rate of progress in determining the functional, pharmacological, neuronal network and whole animal consequences of genetic variants discovered in patients with various types of epilepsy and to develop strategies for establishing diagnostic criteria and identifying potential targets for intervention.

Notice NOT-GM-19-039 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-20-017 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to solicit the research applications for commercializable, digital health-based products that aim at positively affecting the fundamental social and environmental conditions that are risk factors for the populations affected by the use of drugs, including opioids.

Funding Opportunity RFA-DA-20-018 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to solicit the research applications for commercializable, digital health-based products that aim at positively affecting the fundamental social and environmental conditions that are risk factors for the populations affected by the use of drugs, including opioids.

Funding Opportunity RFA-AG-20-029 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications proposing to conduct research involving pragmatic clinical trials into improving the effectiveness of treatment strategies for comorbid conditions that occur frequently in combination with Alzheimers disease and Alzheimer's disease-related dementias (AD/ADRD).